8:22:06 PM PDT - Monday, October 19th, 2020

Fluidigm Soars 16% As Covid-19 Saliva Test Selected In US; Analyst Sees 78% Upside  

By Editor - Sun Oct 18, 1:18 pm

Shares in Fluidigm spiked 16% in Friday’s extended market session after the company’s Covid-19 saliva test was selected by the Trump Administration for use in a US federal program at testing sites in Texas.Waco, Texas, is the first community to offer Covid-19 saliva testing through the US federal program starting October 16. The Fluidigm  (FLDM) saliva test will be offered at 3 sites through mid-November. Fluidigm’s test that uses samples of saliva collected by spitting into a sterile container, detects SARS-CoV-2, the virus that causes Covid-19, on a molecular level using a microfluidics platform.The US federal program provides Covid-19 testing sites for a limited period in areas where there has been a recent and significant increase in the number of new virus cases and hospitalizations.  The program is administered by the U.S. Department of Health and Human Services (HHS) in partnership with local communities and private companies. HHS has shipped 10,000 Fluidigm saliva tests to select Waco, Texas sites.The Fluidigm integrated microfluidics platform used in the saliva test can generate as many as 6,000 test results per day

Read more:

Fluidigm Soars 16% As Covid-19 Saliva Test Selected In US; Analyst Sees 78% Upside

Leave a Reply

You must sign in to post a comment.